Peptides having reduced toxicity that stimulate cholesterol efflux

Bielicki, John K.; Johansson, Jan; Danho, Waleed

Advanced Search OptionsAdvanced Search queries use a traditional Term Search. For more info, see our FAQ.

All Fields:

Patent Title:

Abstract:

Assignee:

Inventor(s):

Patent Number:

Patent Classification (CPC):

All Classifications
A - human necessities
A01 - agriculture
A21 - baking
A22 - butchering
A23 - foods or foodstuffs
A24 - tobacco
A41 - wearing apparel
A42 - headwear
A43 - footwear
A44 - haberdashery
A45 - hand or travelling articles
A46 - brushware
A47 - furniture
A61 - medical or veterinary science
A62 - life-saving
A63 - sports
A99 - subject matter not otherwise provided for in this section
B - performing operations
B01 - physical or chemical processes or apparatus in general
B02 - crushing, pulverising, or disintegrating
B03 - separation of solid materials using liquids or using pneumatic tables or jigs
B04 - centrifugal apparatus or machines for carrying-out physical or chemical processes
B05 - spraying or atomising in general
B06 - generating or transmitting mechanical vibrations in general
B07 - separating solids from solids
B08 - cleaning
B09 - disposal of solid waste
B21 - mechanical metal-working without essentially removing material
B22 - casting
B23 - machine tools
B24 - grinding
B25 - hand tools
B26 - hand cutting tools
B27 - working or preserving wood or similar material
B28 - working cement, clay, or stone
B29 - working of plastics
B30 - presses
B31 - making articles of paper, cardboard or material worked in a manner analogous to paper
B32 - layered products
B33 - additive manufacturing technology
B41 - printing
B42 - bookbinding
B43 - writing or drawing implements
B44 - decorative arts
B60 - vehicles in general
B61 - railways
B62 - land vehicles for travelling otherwise than on rails
B63 - ships or other waterborne vessels
B64 - aircraft
B65 - conveying
B66 - hoisting
B67 - opening, closing {or cleaning} bottles, jars or similar containers
B68 - saddlery
B81 - microstructural technology
B82 - nanotechnology
B99 - subject matter not otherwise provided for in this section
C - chemistry
C01 - inorganic chemistry
C02 - treatment of water, waste water, sewage, or sludge
C03 - glass
C04 - cements
C05 - fertilisers
C06 - explosives
C07 - organic chemistry
C08 - organic macromolecular compounds
C09 - dyes
C10 - petroleum, gas or coke industries
C11 - animal or vegetable oils, fats, fatty substances or waxes
C12 - biochemistry
C13 - sugar industry
C14 - skins
C21 - metallurgy of iron
C22 - metallurgy
C23 - coating metallic material
C25 - electrolytic or electrophoretic processes
C30 - crystal growth
C40 - combinatorial technology
C99 - subject matter not otherwise provided for in this section
D - textiles
D01 - natural or man-made threads or fibres
D02 - yarns
D03 - weaving
D04 - braiding
D05 - sewing
D06 - treatment of textiles or the like
D07 - ropes
D10 - indexing scheme associated with sublasses of section d, relating to textiles
D21 - paper-making
D99 - subject matter not otherwise provided for in this section
E - fixed constructions
E01 - construction of roads, railways, or bridges
E02 - hydraulic engineering
E03 - water supply
E04 - building
E05 - locks
E06 - doors, windows, shutters, or roller blinds in general
E21 - earth drilling
E99 - subject matter not otherwise provided for in this section
F - mechanical engineering
F01 - machines or engines in general
F02 - combustion engines
F03 - machines or engines for liquids
F04 - positive - displacement machines for liquids
F05 - indexing schemes relating to engines or pumps in various subclasses of classes f01-f04
F15 - fluid-pressure actuators
F16 - engineering elements and units
F17 - storing or distributing gases or liquids
F21 - lighting
F22 - steam generation
F23 - combustion apparatus
F24 - heating
F25 - refrigeration or cooling
F26 - drying
F27 - furnaces
F28 - heat exchange in general
F41 - weapons
F42 - ammunition
F99 - subject matter not otherwise provided for in this section
G - physics
G01 - measuring
G02 - optics
G03 - photography
G04 - horology
G05 - controlling
G06 - computing
G07 - checking-devices
G08 - signalling
G09 - education
G10 - musical instruments
G11 - information storage
G12 - instrument details
G16 - information and communication technology [ict] specially adapted for specific application fields
G21 - nuclear physics
G99 - subject matter not otherwise provided for in this section
H - electricity
H01 - basic electric elements
H02 - generation
H03 - basic electronic circuitry
H04 - electric communication technique
H05 - electric techniques not otherwise provided for
H99 - subject matter not otherwise provided for in this section
Y - new / cross sectional technologies
Y02 - technologies or applications for mitigation or adaptation against climate change
Y04 - information or communication technologies having an impact on other technology areas
Y10 - technical subjects covered by former uspc

More Options ...

Title: Peptides having reduced toxicity that stimulate cholesterol efflux

Abstract

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.

Inventors:: Bielicki, John K.; Johansson, Jan; Danho, Waleed

Issue Date:: Tue Sep 15 00:00:00 EDT 2020

Research Org.:: Lawrence Berkeley National Laboratory (LBNL), Berkeley, CA (United States)

Sponsoring Org.:: USDOE

OSTI Identifier:: 1735256

Patent Number(s):: 10774118

Application Number:: 16/020,395

Assignee:: The Regents of the University of California (Oakland, CA)

Patent Classifications (CPCs):: A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS

Show more

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61K - PREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
A61K38/17 - from animals
A61K45/06 - Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
A61K47/544 - {Phospholipids}
A61K47/64 - Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent

A - HUMAN NECESSITIES A61 - MEDICAL OR VETERINARY SCIENCE A61P - SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
A61P13/12 - of the kidneys
A61P25/28 - for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
A61P29/00 - Non-central analgesic, antipyretic or anti-inflammatory agents, e.g antirheumatic agents
A61P3/06 - Antihyperlipidemics
A61P3/10 - for hyperglycaemia, e.g. antidiabetics
A61P9/00 - Drugs for disorders of the cardiovascular system
A61P9/04 - Inotropic agents, i.e. stimulants of cardiac contraction
A61P9/10 - for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis

C - CHEMISTRY C07 - ORGANIC CHEMISTRY C07K - PEPTIDES
C07K14/435 - from animals
C07K14/775 - Apolipopeptides

Show less

DOE Contract Number:: AC02-05CH11231

Resource Type:: Patent

Resource Relation:: Patent File Date: 06/27/2018

Country of Publication:: United States

Language:: English

Subject:: 59 BASIC BIOLOGICAL SCIENCES; 37 INORGANIC, ORGANIC, PHYSICAL, AND ANALYTICAL CHEMISTRY

Citation Formats


                    Bielicki, John K., Johansson, Jan, and Danho, Waleed. Peptides having reduced toxicity that stimulate cholesterol efflux.  United States: N. p., 2020. 
        Web.

Copy to clipboard


                    Bielicki, John K., Johansson, Jan, & Danho, Waleed. Peptides having reduced toxicity that stimulate cholesterol efflux.  United States.

Copy to clipboard


                    Bielicki, John K., Johansson, Jan, and Danho, Waleed. Tue .  
        "Peptides having reduced toxicity that stimulate cholesterol efflux".  United States.  https://www.osti.gov/servlets/purl/1735256.

Copy to clipboard


                    
@article{osti_1735256,

  title        = {Peptides having reduced toxicity that stimulate cholesterol efflux},

  author       = {Bielicki, John K. and Johansson, Jan and Danho, Waleed},

  abstractNote = {The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer's Disease or frontotemporal dementia.},

  doi          = {},

  journal      = {},
number       = ,

  volume       = ,

  place        = {United States},

  year         = {Tue Sep 15 00:00:00 EDT 2020},

  month        = {Tue Sep 15 00:00:00 EDT 2020}

}

Copy to clipboard

Patent:

Save / Share:

Export Metadata

Save to My Library

Works referenced in this record:

Retention of α-helical structure by HDL mimetic peptide ATI-5261 upon extensive dilution represents an important determinant for stimulating ABCA1 cholesterol efflux with high efficiency
journal, November 2013

Zheng, Ying; Patel, Arti B.; Narayanaswami, Vasanthy
Biochemical and Biophysical Research Communications, Vol. 441, Issue 1, p. 71-76
https://doi.org/10.1016/j.bbrc.2013.10.017

Characteristics of the amino acids as components of a peptide hormone sequence
book, January 1976

Rudinger, J.; Parsons, J. A.
Peptide Hormones, p. 1-7
https://doi.org/10.1007/978-1-349-02718-7_1

Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases
patent-application, June 2011

Johansson, Jan O.
US Patent Application 12/976024; 20110152112
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20110152112

Peptides Having Reduced Toxicity Thar Stimulate Cholesterol Efflux
patent-application, September 2014

Bielicki, John K.; Johansson, Jan; Danho, Waleed
US Patent Application 14/216749; 20140287994
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20140287994

Limitations of Peptide Retro-inverso Isomerization in Molecular Mimicry
journal, April 2010

Li, Chong; Pazgier, Marzena; Li, Jing
Journal of Biological Chemistry, Vol. 285, Issue 25
https://doi.org/10.1074/jbc.M110.116814

Sustained-delivery of an apolipoproteinE–peptidomimetic using multivesicular liposomes lowers serum cholesterol levels
journal, February 2002

Ramprasad, Mysore P.; Anantharamaiah, G. M.; Garber, David W.
Journal of Controlled Release, Vol. 79, Issue 1-3, p. 207-218
https://doi.org/10.1016/S0168-3659(01)00552-1

Regulation and Mechanisms of ATP-Binding Cassette Transporter A1-Mediated Cellular Cholesterol Efflux
journal, July 2003

Wang, N.
Arteriosclerosis, Thrombosis, and Vascular Biology, Vol. 23, Issue 7, p. 1178-1184
https://doi.org/10.1161/01.ATV.0000075912.83860.26

Stabilized alpha helical peptides and uses thereof
patent-application, November 2005

Walensky, Loren D.; Korsmeyer, Stanley J.; Korsmeyer, Susan
US Patent Application 10/981873; 20050250680
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20050250680

Methods and reagents for modulating cholesterol levels
patent-application, March 2004

Hayden, Michael R.; Wilson, Angela R. Brooks; Pimstone, Simon N.
US Patent Application 10/617334; 20040058869
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20040058869

Cysteine-containing peptides having antioxidant properties
patent, October 2009

Bielicki, John K.
US Patent Document 7,601,802
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/7601802

A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice
journal, January 2010

Bielicki, John K.; Zhang, Haiyan; Cortez, Yuan
Journal of Lipid Research, Vol. 51, Issue 6, p. 1496-1503
https://doi.org/10.1194/jlr.M003665

Orally administered peptides synergize statin activity
patent-application, April 2008

Fogelman, Alan M.; Anantharamaiah, Gattadahalli M.; Navab, Mohamad
US Patent Application 11/830675; 20080096815
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20080096815

The complete genome sequence of Moorella thermoacetica (f. Clostridium thermoaceticum)
journal, July 2008

Pierce, Elizabeth; Xie, Gary; Barabote, Ravi D.
Environmental Microbiology, Vol. 10, Issue 10, p. 2550-2573
https://doi.org/10.1111/j.1462-2920.2008.01679.x

Effects of l- or d-Pro incorporation into hydrophobic or hydrophilic helix face of amphipathic α-helical model peptide on structure and cell selectivity
journal, February 2004

Song, Yun Mi; Yang, Sung-Tae; Lim, Shin Saeng
Biochemical and Biophysical Research Communications, Vol. 314, Issue 2, p. 615-621
https://doi.org/10.1016/j.bbrc.2003.12.142

Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat
journal, November 2002

Bradley, Christina Marchetti; Barrick, Doug
Journal of Molecular Biology, Vol. 324, Issue 2, p. 373-386
https://doi.org/10.1016/S0022-2836(02)00945-2

Compositions and methods of use for treating cardiovascular disease
patent-application, September 2008

Heinecke, Jay W.; Oram, John F.; Oda, Michael N.
US Patent Application 11/952044; 20080234192
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20080234192

Apolipoprotein E: phospholipid binding studies with synthetic peptides from the carboxyl terminus
journal, February 1992

Sparrow, James T.; Sparrow, Doris A.; Fernando, Germain
Biochemistry, Vol. 31, Issue 4, p. 1065-1068
https://doi.org/10.1021/bi00119a015

Protein Folding: A Glimpse of the Holy Grail?
journal, October 1998

Berendsen, H. J. C.
Science, Vol. 282, Issue 5389, p. 642-643
https://doi.org/10.1126/science.282.5389.642

Helical synthetic peptides that stimulate cellular cholesterol efflux
patent-application, September 2005

Bielicki, John K.; Natarajan, Pradeep
US Patent Application 11/014187; 20050202532
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20050202532

Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
patent-application, July 2005

Sircar, Jagadish C.; Alisala, Kashinatham; Nikoulin, Igor
US Patent Application 10/975157; 20050159362
URL: https://image-ppubs.uspto.gov/dirsearch-public/print/downloadPdf/20050159362

Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox
book, January 1994

Ngo, J. Thomas; Marks, Joe; Karplus, Martin
The Protein Folding Problem and Tertiary Structure Prediction, p. 433-506
https://doi.org/10.1007/978-1-4684-6831-1_14

The C-Terminal Lipid-Binding Domain of Apolipoprotein E Is a Highly Efficient Mediator of ABCA1-Dependent Cholesterol Efflux that Promotes the Assembly of High-Density Lipoproteins
journal, March 2007

Vedhachalam, Charulatha; Narayanaswami, Vasanthy; Neto, Nicole
Biochemistry, Vol. 46, Issue 10, p. 2583-2593
https://doi.org/10.1021/bi602407r

The Positional Specificity of EXXK Motifs within an Amphipathic α-Helix Dictates Preferential Lysine Modification by Acrolein: Implications for the Design of High-Density Lipoprotein Mimetic Peptides
journal, July 2012

Zheng, Ying; Kim, Sea H.; Patel, Arti B.
Biochemistry, Vol. 51, Issue 32, p. 6400-6412
https://doi.org/10.1021/bi300626g

Similar Records in DOE Patents and OSTI.GOV collections:

Peptides having reduced toxicity that stimulate cholesterol efflux

Patent Bielicki, John K.; Johansson, Jan; Danho, Waleed

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia and inflammation.
Full Text Available
Peptides having reduced toxicity that stimulate cholesterol efflux

Patent Bielicki, John K.; Johansson, Jan; Danho, Waleed

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer'smore » Disease or frontotemporal dementia. « less
Full Text Available
Peptides having reduced toxicity that stimulate cholesterol efflux

Patent Bielicki, John K.; Johansson, Jan; Danho, Waleed

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimer'smore » Disease or frontotemporal dementia. « less
Full Text Available
Peptides having reduced toxicity that stimulate cholesterol efflux

Patent Bielicki, John K.; Johansson, Jan

The present invention provides a family of non-naturally occurring polypeptides having cholesterol efflux activity that parallels that of full-length apolipoproteins (e.g., Apo AI and Apo E), and having high selectivity for ABCA1 that parallels that of full-length apolipoproteins. Further, the peptides of the invention have little or no toxicity when administered at therapeutic and higher doses. The invention also provides compositions comprising such polypeptides, methods of identifying, screening and synthesizing such polypeptides, and methods of treating, preventing or diagnosing diseases and disorders associated with dyslipidemia, hypercholesterolemia, or inflammation; or diseases involving abnormal glucose metabolism, e.g., diabetes, metabolic syndrome; or Alzheimersmore » Disease or frontotemporal dementia. « less
Full Text Available
Helical synthetic peptides that stimulate cellular cholesterol efflux

Patent Bielicki, John K.; Natarajan, Pradeep

The present invention provides peptides comprising at least one amphipathic alpha helix and having an cholesterol mediating activity and a ABCA stabilization activity. The invention further provides methods of using such peptides.
Full Text Available

Similar Records

Title: Peptides having reduced toxicity that stimulate cholesterol efflux

Abstract

Citation Formats

Retention of α-helical structure by HDL mimetic peptide ATI-5261 upon extensive dilution represents an important determinant for stimulating ABCA1 cholesterol efflux with high efficiency journal, November 2013

Characteristics of the amino acids as components of a peptide hormone sequence book, January 1976

Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases patent-application, June 2011

Peptides Having Reduced Toxicity Thar Stimulate Cholesterol Efflux patent-application, September 2014

Limitations of Peptide Retro-inverso Isomerization in Molecular Mimicry journal, April 2010

Sustained-delivery of an apolipoproteinE–peptidomimetic using multivesicular liposomes lowers serum cholesterol levels journal, February 2002

Regulation and Mechanisms of ATP-Binding Cassette Transporter A1-Mediated Cellular Cholesterol Efflux journal, July 2003

Stabilized alpha helical peptides and uses thereof patent-application, November 2005

Methods and reagents for modulating cholesterol levels patent-application, March 2004

Cysteine-containing peptides having antioxidant properties patent, October 2009

A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice journal, January 2010

Orally administered peptides synergize statin activity patent-application, April 2008

The complete genome sequence of Moorella thermoacetica (f. Clostridium thermoaceticum) journal, July 2008

Effects of l- or d-Pro incorporation into hydrophobic or hydrophilic helix face of amphipathic α-helical model peptide on structure and cell selectivity journal, February 2004

Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat journal, November 2002

Compositions and methods of use for treating cardiovascular disease patent-application, September 2008

Apolipoprotein E: phospholipid binding studies with synthetic peptides from the carboxyl terminus journal, February 1992

Protein Folding: A Glimpse of the Holy Grail? journal, October 1998

Helical synthetic peptides that stimulate cellular cholesterol efflux patent-application, September 2005

Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia patent-application, July 2005

Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox book, January 1994

The C-Terminal Lipid-Binding Domain of Apolipoprotein E Is a Highly Efficient Mediator of ABCA1-Dependent Cholesterol Efflux that Promotes the Assembly of High-Density Lipoproteins journal, March 2007

The Positional Specificity of EXXK Motifs within an Amphipathic α-Helix Dictates Preferential Lysine Modification by Acrolein: Implications for the Design of High-Density Lipoprotein Mimetic Peptides journal, July 2012

Retention of α-helical structure by HDL mimetic peptide ATI-5261 upon extensive dilution represents an important determinant for stimulating ABCA1 cholesterol efflux with high efficiency
journal, November 2013

Characteristics of the amino acids as components of a peptide hormone sequence
book, January 1976

Diagnosis and treatment of reverse cholesterol transport deficiency-related diseases
patent-application, June 2011

Peptides Having Reduced Toxicity Thar Stimulate Cholesterol Efflux
patent-application, September 2014

Limitations of Peptide Retro-inverso Isomerization in Molecular Mimicry
journal, April 2010

Sustained-delivery of an apolipoproteinE–peptidomimetic using multivesicular liposomes lowers serum cholesterol levels
journal, February 2002

Regulation and Mechanisms of ATP-Binding Cassette Transporter A1-Mediated Cellular Cholesterol Efflux
journal, July 2003

Stabilized alpha helical peptides and uses thereof
patent-application, November 2005

Methods and reagents for modulating cholesterol levels
patent-application, March 2004

Cysteine-containing peptides having antioxidant properties
patent, October 2009

A new HDL mimetic peptide that stimulates cellular cholesterol efflux with high efficiency greatly reduces atherosclerosis in mice
journal, January 2010

Orally administered peptides synergize statin activity
patent-application, April 2008

The complete genome sequence of Moorella thermoacetica (f. Clostridium thermoaceticum)
journal, July 2008

Effects of l- or d-Pro incorporation into hydrophobic or hydrophilic helix face of amphipathic α-helical model peptide on structure and cell selectivity
journal, February 2004

Limits of Cooperativity in a Structurally Modular Protein: Response of the Notch Ankyrin Domain to Analogous Alanine Substitutions in Each Repeat
journal, November 2002

Compositions and methods of use for treating cardiovascular disease
patent-application, September 2008

Apolipoprotein E: phospholipid binding studies with synthetic peptides from the carboxyl terminus
journal, February 1992

Protein Folding: A Glimpse of the Holy Grail?
journal, October 1998

Helical synthetic peptides that stimulate cellular cholesterol efflux
patent-application, September 2005

Mediators of reverse cholesterol transport for the treatment of hypercholesterolemia
patent-application, July 2005

Computational Complexity, Protein Structure Prediction, and the Levinthal Paradox
book, January 1994

The C-Terminal Lipid-Binding Domain of Apolipoprotein E Is a Highly Efficient Mediator of ABCA1-Dependent Cholesterol Efflux that Promotes the Assembly of High-Density Lipoproteins
journal, March 2007

The Positional Specificity of EXXK Motifs within an Amphipathic α-Helix Dictates Preferential Lysine Modification by Acrolein: Implications for the Design of High-Density Lipoprotein Mimetic Peptides
journal, July 2012